

Based on Form PTO-1449  
(3/90)

ATTY. DOCKET NO.

910000-2020

SERIAL NO.

LIST OF REFERENCES CITED BY APPLICANT  
(Use several sheets if necessary)

APPLICANT

Detmar et al.

FILING DATE

03/30/01

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
my	AA	USSN 09/536,087	3/24/00	Detmar and Streit			
L	AB	USSN 60/137,221	3/31/99	Detmar and Streit			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
W	AC	WO 94/00133	1/06/94	WIPO				

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

my	AD		Gilbert et al., "Cell transportation of genetically altered cells on biodegradable polymer scaffolds in syngeneic rats" Transplantation, vol. 56, 2 August 1998, pgs 423-427.					
	AE		Qin et al., "Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice" Proc. Natl. Acad. Sci. USA, vol. 95, November 1998, pgs 14411-14416.					
	AF		Cao et al., "Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases" J. Clin. Invest., vol. 101, no. 5, 5 March 1998, pgs 1055-1063.					
	AG		Vacanti & Langer, "Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation" The Lancet, vol. 34, no. Suppl.24 July 1999, pgs 32-34.					
	AH		Stephen et al., "Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo" Proc. Natl. Acad. Sci. USA, vol. 98, no. 6, 13 March 2001, pgs 3214-3219.					
	AI		Detmar et al. "Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasis" J. Exp. Med. Vol. 180: 1141-1146.					
	AJ		Jackson et al. (1997) "The codependence of angiogenesis and chronic inflammation" 11(6):457-464.					
	AK		Vacanti et al. "Selective cell transplantation using bioabsorbable artificial polymers as matrices" (1988) Journal of Pediatric Surgery 23(1): 3-9.					
	AL		Locopo et al. "Clinical significance of angiogenic factors in breast cancer" (1998) Breast Cancer Research and Treatment 52: 159-173.					
	AM		Streit et al. "Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis" (1999) PNAS 96(26) 14888-14893.					
	AN		Lange-Asachenfeldt et al. (2002) "Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2-deficient mice" Blood 99(2) 538-545.					
	AO		Martin, P., Science 276, 671-674 (1997)					
	AP		O'Reilly, M., et al., Nature Med. 2, 689-692 (1996)					

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449  
(3/90)LIST OF REFERENCES CITED BY APPLICANT  
(Use several sheets if necessary)

ATTY. DOCKET NO.

910000-2020

SERIAL NO.

APPLICANT

Detmar et al.

FILING DATE

March 30, 2002

GROUP

To Be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
my	AQ	4,404,199	9/13/83	Bonaldi et al.			
	AR	4,487,833	12/11/84	Donahoe et al.			
	AS	4,510,131	4/9/85	Donahoe et al.			
	AT	4,753,794	6/28/88	Donahoe et al.			
	AU	4,792,601	12/20/88	Donahoe et al.			
	AV	5,011,687	4/30/91	Donahoe et al.			
	AW	5,047,336	9/10/91	Cate et al.			
	AX	5,198,420	3/30/93	Donahoe et al.			
	AY	5,661,126	8/26/97	Donahoe et al.			
	AZ	5,204,055	4/20/93	Sachs et al.			
	BA	5,759,830	6/2/98	Vacanti et al.			
	BB	5,709,854	01/20/98	Griffith-Cima et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
my	BC	WO 94/25080	11/10/94	WIPO				
	BD	WO 93/17669	09/16/93	WIPO				
	BE	WO 96/40002	12/19/96	WIPO				

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

my	BF	Budzik et al. (1983) "Mullerian Inhibiting Substance Fractionation by dye affinity Chromatography" Cell, vol. 34: 304-314.
	BG	Boveri et al. (1993) "Transfection of the Mullerian Inhibiting Substance gene inhibits local and metastatic tumor growth" International Journal of Oncology 2: 135-143
	BH	Bogden et al. (1979) "Growth of Human Tumor Xenografts Implanted under the Renal Capsule of Normal Immunocompetent Mice" Expl Cell Biol. 47: 281-293
	BI	Chin et al. (1991) "Human Mullerian Inhibiting Substance Inhibits Tumor Growth in Vitro and in Vivo" Cancer Research 51: 2101-2106.
	BJ	Cate et al. (1986) "Development of Mullerian Inhibiting Substance as an Anti-cancer Drug" Cold Spring Harbor Symposia on Quantitative Biology, Volume LI: 641-647.
	BK	Cate et al. (1986) "Isolation of the Bovine and Human Genes for Mullerian Inhibiting Substance and Expression of the Human Gene in Animal Cells" Cell, vol 45: 685-698

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
AUG 22 2002  
TECH CENTER 1600/2600  
09/822,165

Based on Form PTO-1449 (3/90)  LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.  910000-2020	SERIAL NO.
	APPLICANT  Detmar et al.	
	FILING DATE  March 30, 2002	GROUP  To Be Assigned

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

my	BL	Donahoe et al. (1979) "Mullerian Duct Regression in the Embryo Correlated with Cytotoxic Activity Against Human Ovarian Cancer" Science, vol. 205:913-915
	BM	Donahoe et al. (1977) "A graded organ culture assay for the detection of Mullerian Inhibiting Substance" Journal of Surgical Research 23: 141-148
	BN	Donahoe et al. (1981) "Mullerian Inhibiting Substance Inhibits Growth of a Human Ovarian Cancer in Nude Mice" Annual Meeting of the American Surgical Association, Chicago, Illinois, April 22-24, 1981, 472-480.
	BO	Fuller et al. (1998) "Mullerian Inhibiting Substance Reduction of Colony Growth of Human Gynecologic Cancers in a Stem Cell Assay" Gynecologic Oncology 22: 135-148
	BP	Fingert et al. (1987) "Rapid growth of human cancer cells in a mouse model with Fibrin Clot Subrenal Capsule Assay" Cancer Research 47:3824-3829.
	BQ	Gustafson, M (1992) "Mullerian Inhibiting Substance as a marker for Ovarian sex-cord tumor," The New England Journal of Medicine. vol. 326(7): 466-471.
	BR	Fuller et al., (1982) "Mullerian inhibiting Substance Inhibits Colony Growth of a Human Ovarian Carcinoma Cell Line" Journal of Clinical Endocrinology and Metabolism vol. 54(5): 1051-1055
	BS	Hudson et al., (1990) "An Immunoassay to Detect Human Mullerian Inhibiting Substance in Males and Females during Normal Development" Journal of Clinical Endocrinology and Metabolism, vol. 70(1), 16-22
	BT	Kurian et al. (1995) "Cleavage of Mullerian Inhibiting Substance Activates Antiproliferative Effects in Vivo" vol. 1, 343-349
	BU	Lee, M et al. (1996) "Mullerian Inhibiting substance in humans: Normal Levels from Infancy to Adulthood" Journal of Clinical Endocrinology and Metabolism, vol. 81(2):571-576
	BV	Masiakos et al. (1999) "Human Ovarian Cancer, Cell lines, and primary ascites Cells Express the Human Mullerian Inhibiting Substance (MIS) Type II Receptor, Bind, and are responsive to MIS" Clinical Cancer Research, vol. 5, 3488-3499
	BW	MacLaughlin et al. (1991) "Bioassay, Purification, Cloning and Expression of Mullerian Inhibiting Substance" Methods in Enzymology, vol. 198: 358-369
	BX	MacLaughlin et al. (1992) "Mullerian Duct Regression and Antiproliferative Bioactivities of Mullerian Inhibiting Substance Reside in its Carboxy-Terminal Domain" Endocrinology, vol. 131(1): 291-296
	BY	O'Reilly et al. (1999) "Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin" Science, vol. 285: 1926-1928
	BZ	Pepinsky, R., (1988) "Proteolytic processing of Mullerian Inhibiting Substance produces a transforming growth factor-B-like Fragment." The Journal of Biological Chemistry, vol. 263(35): 18961-18964
	CA	Parry et al. (1992) "Recombinant Human Mullerian Inhibiting Substance Inhibits Human Ocular Melanoma Cell Lines in vitro and in vivo" Cancer Research, vol. 52: 1182-1186
	CB	Ragin, R., (1992) "Human Mullerian Inhibiting Substance: Enhanced Purification Imparts Biochemical Stability and Restores Antiproliferative Effects" Protein Expression and Purification 3: 236-245
	CC	Teixeira, J. and Donahoe, P., (1996) "Molecular Biology of MIS and Its Receptors" Journal of Andrology, vol. 17(4): 336-341
	CD	Teixera, J. et al. (1996) "Developmental Expression of a Candidate Mullerian Inhibiting Substance Type II Receptor", Endocrinology, vol. 137(1): 160-165
	CE	Teixeira, J. (1999) "Transcriptional regulation of the rat Mullerian inhibiting substance type II receptor in rodent Leydig cells" PNAS, vol. 96(24) 13831-13838
	CF	Chamberlain, et al. Biomaterials(1998) 19: 1393-1403.
	CG	Hadlock et al. Laryngoscope (1999) 109(9): 1412-1416.

EXAMINER  <i>Misook Y</i>	DATE CONSIDERED  3-17-03
---------------------------------	--------------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449  
(3/90)

ATTY. DOCKET NO.

SERIAL NO.

910000-2020

APPLICANT

Detmar et al.

FILING DATE

March 30, 2002

GROUP

To Be Assigned

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CH	Kristjansen, P.E. et al. Microvasc. Res. 48, 389-402 (1994)
CI	Matsuda et al. ASAIO, 38: 154-157 (1992)
CJ	Wells et al., Exp. Neurol. (1997) 146(2): 395-402
CK	Woerly et al., (1999) J. Tissue Engineering 5(5): 467-488
CL	Albo et al: Surgery 1997, 122: 493-500
CM	Albo et al. Biochem Biophys Res Commun 1994, 203: 857-65
CN	Anderson, W.F., Human gene therapy. Nature 392 (6679 Suppl.), 25-30 (1998)
CO	Berger, A.C. et al., J. Surg. Res. 91, 26-31 (2000)
CP	Boehm, T., et al. Nature 390, 404-407 (1997)
CQ	Bornstein et al., J Cell Biol 1995, 130: 503-506
CR	Bornstein FASEB J 1992, 6: 3290-3299
CS	Brown LF et al., Exs 1997, 79: 233-269
CT	Crystal, R.G. Nat Biotechnol. 17, 336-337 (1999)
CU	Carmeliet, D. et al. Nature 407, 249-257 (2000)
CV	Christofori, Angiogenesis 1998, 2:21-23
CW	Claffey et al. Cancer Res 1996, 56: 172-78
CX	Despont, et al., "High-Aspect-Ratio, Ultrathick, Negative-Tone Near-UV Photoresist for MEMS," Proc. of IEEE 10 <sup>th</sup> Annual International Workshop on MEMS, Nagoya, Japan, pgs 518-522 (Jan 26-30, 1997)
CY	Drixler, T.A. et al., Cancer Res. 60, 1761-1765 (2000)
CZ	Feldman, A.L. et al. Cancer 89, 1181-1194 (2000)
DA	Ferrara et al. Breast Cancer Res Treat 1995, 36: 127-137
DB	Goodson et al., proc Natl Acad Sci USA 1994. 91: 7129-7133
DC	Hahnfeldt, P., et al. Cancer Res. 59, 4770-4775 (1999)
DD	Hanahan D. and Folkman J. Cell 1996, 86: 353-364
DE	Iruela-Arispe et al., Proc Natl Acad Sci USA 1991, 88: 5026-5030
DF	Kerbel, R.S. Carcinogenesis 21: 505-515(2000)
DG	Kaufman (1987) EMBO J. 6: 187-195
DH	Lawler, J. Curr. Opin. Cell Biol. 12, 634-640 (2000)
DI	Murphy-Ullrich, J.E., et al., J. Biol. Chem. 268, 26784-26789 (1993)
DJ	Gorczyca et al. Cancer Res. 1993, 53: 1945-51

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



ATTY. DOCKET NO.

SERIAL NO.

910000-2020

**09/822,161**

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

**APPLICANT**

Detmar et al.

FILING DATE

GROUP

**March 30, 2002**

1642

## U.S. PATENT DOCUMENTS

RECEIVED

DEC 05 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

TRANSLATION

**YES**

NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AA

Cherrington, et al. (2000) "New Paradigms for the Treatment of Cancer: The Role of Anti-angiogenesis agents" *Adv. Cancer Res.* 79:1-38.

**EXAMINER**

DATE CONSIDERED

3-17-03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.